


## PHARMACEUTICAL 2021



## Amneal Pharmaceuticals Inc. Rank 104 of 409





## PHARMACEUTICAL 2021



## Amneal Pharmaceuticals Inc. Rank 104 of 409

The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 248% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 371% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,551,539
Cost of Goods Sold	1,329,551
Intangible Assets	1,827,440
Liabilities, Current	676,902
Liabilities, Non-Current	2,972,395
Other Assets	149,300
Other Compr. Net Income	-18,722
Other Expenses	-45,058
Other Liabilities	0
Other Net Income	-132,795
Property and Equipment	477,754
Research and Development	179,930
Revenues	1,992,523
Selling, General and Administrative Expense	326,727

Output Variable	Value in 1000 USD
Assets	4,006,033
Liabilities	3,649,297
Expenses	1,791,150
Stockholders Equity	356,736
Net Income	68,578
Comprehensive Net Income	59,217
Economic Capital Ratio	17%